Shares of commercial-stage biotech Geron (NASDAQ: GERN) couldn’t quite surmount the hump of Hump Day. After the company released its latest set of quarterly figures, its stock price wobbled as investors determined how best to digest the results. Finally, the stock closed on a downbeat note, booking a 0.8% loss on the day and comparing unfavorably to the slight (0.4%) gain of the S&P 500 index.
Rytelo brings in revenue
Geron unveiled its first-quarter numbers well before market open, showing that the oncology-focused biotech earned $39.6 million during the period. Nearly all of this was derived from sales of Rytelo, the company’s cancer drug that won Food and Drug Administration (FDA) approval in June 2024. Year-over-year comparisons are therefore meaningless, as the company had no product revenue in the first quarter of 2024.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Image source: Getty Images.
On the bottom line, now that Geron has a revenue stream, thanks to Rytelo, the company’s net loss narrowed to $19.8 million ($0.03 per share) from the year-ago quarter’s $55.4 million.
Analysts tracking the company’s fortunes were clearly expecting notably higher take-up of the drug, however. On average, they were modeling just under $50.5 million for total revenue. By contrast, their estimate for net loss was in line at $0.03.
Geron waxed bullish on Rytelo’s future. In the earnings release, Geron quoted interim president and CEO Dawn Bir saying, “We have received positive feedback from clinicians who have utilized Rytelo, supporting its strong therapeutic profile. We’ve identified specific opportunities and are making focused investments that we believe will strengthen the U.S. commercial trajectory.“
Existing guidance maintained
Geron also maintained its existing guidance for operating expenses. It estimates that these will come in at $270 million to $285 million for the entirety of this year. It added that its current level of cash, equivalents, and marketable securities will suffice “to fund projected operating requirements for the foreseeable future.” It did not get more specific.
Should you invest $1,000 in Geron right now?
Before you buy stock in Geron, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Geron wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $613,546!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $695,897!*
Now, it’s worth noting Stock Advisor’s total average return is 893% — a market-crushing outperformance compared to 162% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of May 5, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
